LC determination of moclobemide and three metabolites in plasma

被引:12
作者
Misztal, G
Skibinski, R
Olajossy, M
Paw, B
机构
[1] Med Acad, Fac Pharm, Dept Med Chem, PL-20093 Lublin, Poland
[2] Med Acad, Psychiat Clin, PL-20442 Lublin, Poland
关键词
moclobemide; HPLC; plasma; assay; solid phase extraction;
D O I
10.1016/S0731-7085(02)00459-4
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Moclobemide and three metabolites were quantified using 1 ml of plasma and solid-phase extraction with Bakerbond CN column after the addition of nadolol as the internal standard (I.S.). Separation and detection the analysed substances were achieved isocratically with acetonitrile-methanol-0.067 M phosphate buffer pH 2.65-0.4% triethylamine (12.7:1.9:85:0.4, v/v/v/v), a Nova-pak C-8 column and UV detection at 230 nm. The lower limits of quantitation for moclobemide was 10 ng ml(-1), for M1 (Ro 16-3177)-8 ng ml(-1), for M2 (Ro 12-5637)-10 ng ml(-1) and for M3 (Ro 12-8095)-15 ng ml(-1) (as the metabolites). Accuracies calculated of three concentrations in each of three separate runs were between 84.55 and 93.68 for moclobemide, 83.28 and 92.30 for M1, 86.31 and 92.66 for M2 and 88.42 and 93.40 for M3. Precision data within day were between 5.71 and 7.50 for moclobemide, 2.91 and 6.58 for M1, 4.98 and 6.40 for M2 and 0.94 and 4.73 for M3. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:1277 / 1285
页数:9
相关论文
共 12 条
[1]   SURFACE SILANOLS IN SILICA-BONDED HYDROCARBONACEOUS STATIONARY PHASES .2. IRREGULAR RETENTION BEHAVIOR AND EFFECT OF SILANOL MASKING [J].
BIJ, KE ;
HORVATH, C ;
MELANDER, WR ;
NAHUM, A .
JOURNAL OF CHROMATOGRAPHY, 1981, 203 (JAN) :65-84
[2]   MODELING THE MARKET UPTAKE OF NEW DRUGS FOLLOWING LISTING FOR SUBSIDY IN AUSTRALIA - A REPORT FROM THE DRUG-UTILIZATION-SUBCOMMITTEE OF THE AUSTRALIAN-PHARMACEUTICAL-BENEFITS-ADVISORY-COMMITTEE [J].
BIRKETT, DJ ;
MCMANUS, P .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 40 (04) :407-410
[3]  
Da Prada M, 1983, Mod Probl Pharmacopsychiatry, V19, P231
[4]  
DAPRADA M, 1989, J PHARMACOL EXP THER, V248, P400
[5]   DETERMINATION OF THE NEW MONOAMINE-OXIDASE INHIBITOR MOCLOBEMIDE AND 3 OF ITS METABOLITES IN BIOLOGICAL-FLUIDS BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
GESCHKE, R ;
KORNER, J ;
EGGERS, H .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1987, 420 (01) :111-120
[6]  
HAUNDA L, 1997, XAOWU FENXI ZAZHI, V17, P3
[7]   High-performance liquid chromatography-electrospray ionization mass spectrometry method for the measurement of moclobemide and two metabolites in plasma [J].
Hoskins, JM ;
Gross, AS ;
Shenfield, GM ;
Rivory, LP .
JOURNAL OF CHROMATOGRAPHY B, 2001, 754 (02) :319-326
[8]  
KIEL JS, 1985, J CHROMATOGR, V320, P313
[9]   MEASUREMENT OF MOCLOBAMIDE, A NEW MONOAMINE-OXIDASE INHIBITOR, BY GAS-CHROMATOGRAPHY WITH NITROGEN-SELECTIVE DETECTION [J].
MAGUIRE, KP ;
NORMAN, TR ;
DAVIES, BM ;
BURROWS, GD .
JOURNAL OF CHROMATOGRAPHY, 1983, 278 (02) :429-433
[10]  
RAAFLAUB J, 1984, ARZNEIMITTEL-FORSCH, V34-1, P80